{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5e81d0643b9a0dd40f9937b2/6aa92184fca3d5c77b4f5b6b?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":" What is the rationale for the development of tandem CAR T-cell therapies?","description":"<p>The Lymphoma Hub was pleased to speak with Peter Borchmann, University Hospital Cologne, DE. We asked, What is the rationale for the development of tandem chimeric antigen receptor (CAR) T-cell therapies? </p><p><br></p><p>Intended for healthcare professionals. This educational resource is independently supported by Miltenyi Biomedicine. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.</p>","author_name":"Scientific Education Support"}